Today, the European Commission is launching the European Health Emergency preparedness and Response Authority (HERA) to prevent, detect, and rapidly respond to health emergencies.
The HERA will anticipate threats and potential health crises, through intelligence gathering and building the necessary response capacities. When an emergency hits, HERA will ensure the development, production and distribution of medicines, vaccines and other medical countermeasures – such as gloves and masks – that were often lacking during the first phase of the coronavirus response. The HERA is a key pillar of the European Health Union announced by President Ursula von der Leyen in her 2020 State of the Union address and will fill a gap in the EU's health emergency response and preparedness.
The HERA activities will rely on a budget of 6 billion euros ($7.1 billion) from the current Multiannual Financial Framework for the period 2022-2027, part of which will come from the NextGenerationEU top-up.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze